Valuation, Transaction Support & Strategy in Life Sciences & Healthcare

Who We Are

Elm Innovation Advisors is a boutique strategy and financial advisory firm built for the industries where complexity, capital, and innovation intersect. We serve early-stage and mature companies in life sciences, healthcare, and technology - alongside the investors, bankers, and legal advisors who support them.

Our work focuses on high-stakes moments. We offer a set of services that address the circumstances and decisions where significant value can be created. We advise on fundamental strategy questions and fundraising/partnering/M&A. Additionally, we offer contract senior executive services in finance and commercialization.

In select situations, we make private investments in early-stage companies where we believe our insight, involvement, and conviction can accelerate growth and enterprise value.

What We Do

We combine deep industry expertise with rigorous analysis to support strategy and execution across the venture lifecycle. Our core advisory services include:

• Strategy

• Transaction Support

• Valuation

• Advanced Modeling

• Market Characterization

• Pricing & Access

• Internal Operations

• Dispute Resolution

We work in sectors that demand both intellectual depth and real-world execution. Our team brings years of experience advising and operating in these industries:

• Life Sciences

• Healthcare

• Technology

We understand the nuances that drive valuation, differentiation, and partner interest in all the industries that we serve.

Industry Expertise

Our Clients

We understand the nuances that drive valuation, differentiation, and partner interest in each domain.

Our clients include:

Founders, executives, and boards

Venture and growth investors

Investment banks

Legal advisors

We work across the innovation ecosystem, supporting those building the future.

Excellence | Enablement | Urgency

Recent Thought Pieces

Interpreting JPM 2026:

Why the Absence of Headlines Does Not Reflect the Absence of Activity

JPM 2026 lacked splashy deal headlines, but Elm Innovation Advisors sees strong underlying momentum. Conference discussions advanced transactions, sharpened valuation and structure, and reflected disciplined capital deployment. Announcements lag activity; preparation dominates. The healthcare market is forming deals now, with visibility likely later in 2026.

Return on Investment for AI-Enabled R&D

A look at how lessons from HTS may guide our understanding of future value

This white paper argues that even if AI drug discovery initially mirrors the pattern seen with HTS, its broader capabilities provide a path beyond candidate discovery, enabling improved clinical outcomes and potentially shifting how therapeutic success is measured and achieved. Thus, early ROI similarities between HTS and AI-enabled discovery are likely to diverge as more data becomes available, and economic returns will be realized in materially different ways.